Question 1

What are the potential benefits and risks of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from Xeloda and Avastin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer does not respond to this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any costs or insurance considerations I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer clinical trial (NCT00121836). Contact the study team or your healthcare provider for specific answers.

What this study is about